Jeff Jonker has been appointed president and CEO of Ambys Medicines. Jonker comes to the Redwood City, CA-based biotech from NGM Bio, where he was president. His experience also includes senior positions at Theravance Biopharma (NASDAQ: TBPH), Satori Pharmaceuticals, and Genentech. Ambys is developing treatments for liver diseases. In August, Ambys launched with a $60 million Series A funding round and a broad partnership with Takeda Pharmaceutical (OTCMKTS: TKPYY).